Bumetanide
Sulfonamides, Plain
Sold as BURINEX
- Drug class
- Sulfonamides, Plain
- Availability
- Prescription only
- Routes
- Oral, Intramuscular, Intravenous
- Markets covered
- 3
- Products on record
- 16
- FDA reports (12 mo)
- 1,749
Overview
Plain-language summary, compiled from the cited regulatory records
Bumetanide is a medication belonging to the sulfonamide drug class [1]. It is approved for the treatment of edema, which is swelling caused by fluid retention, associated with several conditions [1]. These include congestive heart failure, liver disease, and kidney disease, as well as nephrotic syndrome [1].
Bumetanide can be administered orally, intramuscularly, or intravenously [1]. The diuretic response is nearly equal regardless of whether it is taken by mouth or injected [1]. This means that if a patient is not absorbing the medication well through their gastrointestinal tract, or if oral administration is not feasible, the injectable form should be used [1].
In the past 12 months, there have been 1749 adverse event reports for bumetanide [2]. Common adverse events reported include dyspnoea, diarrhoea, headache, fatigue, and nausea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 9 | May 1, 2026 |
| GB United Kingdom | MHRA | 5 | April 10, 2026 |
| CA Canada | Health Canada | 2 | April 23, 2026 |
USUnited States· FDA
9 products
Uses
INDICATIONS AND USAGE
Bumetanide tablets, USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide.
Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets, USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
How to take
GBUnited Kingdom· MHRA
5 products
Uses
g. congestive heart failure, renal dysfunction including nephrotic syndrome and cirrhosis of the liver in adults. In oedema of renal or cardiac origin where high doses of a potent short - acting diuretic are required, Bumetanide 5 mg may be used in adults.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Bumetanide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 542. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 056be255-5880-48… · revised January 8, 2025 [PDF]
- [2]MHRA (UK) · PL045690434 · revised April 10, 2026
- [3]Health Canada (DPD) · 00728276 · revised April 23, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.